Evofem Achieves Profitability with $0.3M Net Income, $20.2M Sales in FY25
Summary
Evofem Biosciences reported a significant financial turnaround for fiscal year 2025, achieving a net income of $0.3 million, a substantial improvement from a $9.0 million net loss in the prior year. The company also posted income from operations of $3.4 million, reversing a $7.7 million operating loss in 2024. This positive shift was driven by record net sales of $20.2 million, marking the fifth consecutive year of sales growth, primarily from its PHEXX contraceptive gel. The company also reduced total operating expenses by 38%. This move to profitability and sustained sales growth represents a material positive development for the micro-cap company, likely impacting investor sentiment.
At the time of this announcement, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.01 to $0.02. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.